Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urologic Neoplasms 1Neoplasms 1Myasthenia Gravis 1Melanoma 1Limbic Encephalitis 1Hematologic Neoplasms 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Colonic Neoplasms 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Immunoglobulins, Intravenous × Clear all
NCT00294476 2006-10-12

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

GammaCan

Phase 2 Unknown
30 enrolled
DermatologicGastrointestinalGenitourinary

Colonic Neoplasms, Melanoma, Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡